PAVmed Inc.

Good morning, and welcome to PubMed's second quarter 2024 business update conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press the star zero for the operator. Please note this event is being recorded. I would now like to turn the conference over to Matt Riley, PubMed Director of Investor Relations. Please go ahead.

Thank you, Operator, and good morning, everyone.

Thank you for participating in today's business update call. Joining me today on the call are Dr. Leshawn Acklock, Chairman and Chief Executive Officer of PavMed, along with Dennis McGrath, Chief Financial Officer of PavMed. The press release announcing our business update and financial results is available on PavMed's website. Please take a moment to read the disclaimers about forward-looking statements in the press release. The business update, press release, and the conference call all include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings of the Securities and Exchange Commission. For a list and a description of these and other important risks and uncertainties that may affect future operations, Part 1, Item 1A, entitled Risk Factors in PAVMED's Most Recent Annual Report on Forms 10-K, filed with the SEC, and any subsequent updates filed in the quarterly reports on Forms 10-Q and subsequent Forms 8-K. Except as required by law, PAVMED disclaims any intentions or obligations to publicly update or revise any forwarding statements to reflect changes in expectations or in events, conditions, or circumstances on which expectations may be based. or that may affect the likelihood that actual results will differ from those contained in the foregoing statements. I would now like to turn the call over to Dr. Elisha Nakhlog, Chairman and CEO of PadMed. Take it away, Elisha.